JP2003525018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003525018A5 JP2003525018A5 JP2000576021A JP2000576021A JP2003525018A5 JP 2003525018 A5 JP2003525018 A5 JP 2003525018A5 JP 2000576021 A JP2000576021 A JP 2000576021A JP 2000576021 A JP2000576021 A JP 2000576021A JP 2003525018 A5 JP2003525018 A5 JP 2003525018A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- protein
- acid sequence
- substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001413 amino acids Chemical group 0.000 description 88
- 238000000034 method Methods 0.000 description 76
- 235000001014 amino acid Nutrition 0.000 description 46
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 40
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 40
- 238000006467 substitution reaction Methods 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 25
- 239000000556 agonist Substances 0.000 description 18
- 239000004031 partial agonist Substances 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 13
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 12
- 239000004472 Lysine Substances 0.000 description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 12
- 235000004279 alanine Nutrition 0.000 description 12
- 229960001230 asparagine Drugs 0.000 description 12
- 235000009582 asparagine Nutrition 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 229960000310 isoleucine Drugs 0.000 description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 11
- 208000027866 inflammatory disease Diseases 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001294 alanine derivatives Chemical class 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- 150000001508 asparagines Chemical class 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 108091006027 G proteins Proteins 0.000 description 4
- 102000030782 GTP binding Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000037041 intracellular level Effects 0.000 description 4
- 150000002519 isoleucine derivatives Chemical class 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 101000738506 Homo sapiens Psychosine receptor Proteins 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 102000048033 human GPR65 Human genes 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 150000003148 prolines Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
Applications Claiming Priority (65)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/170,496 | 1998-10-13 | ||
| US09/170,496 US6555339B1 (en) | 1997-04-14 | 1998-10-13 | Non-endogenous, constitutively activated human protein-coupled receptors |
| US10802998P | 1998-11-12 | 1998-11-12 | |
| US60/108,029 | 1998-11-12 | ||
| US10921398P | 1998-11-20 | 1998-11-20 | |
| US60/109,213 | 1998-11-20 | ||
| US11006098P | 1998-11-27 | 1998-11-27 | |
| US60/110,060 | 1998-11-27 | ||
| US12041699P | 1999-02-16 | 1999-02-16 | |
| US60/120,416 | 1999-02-16 | ||
| US12185299P | 1999-02-26 | 1999-02-26 | |
| US60/121,852 | 1999-02-26 | ||
| US12394599P | 1999-03-12 | 1999-03-12 | |
| US12394999P | 1999-03-12 | 1999-03-12 | |
| US12394499P | 1999-03-12 | 1999-03-12 | |
| US12394699P | 1999-03-12 | 1999-03-12 | |
| US12394899P | 1999-03-12 | 1999-03-12 | |
| US12395199P | 1999-03-12 | 1999-03-12 | |
| US60/123,948 | 1999-03-12 | ||
| US60/123,951 | 1999-03-12 | ||
| US60/123,944 | 1999-03-12 | ||
| US60/123,946 | 1999-03-12 | ||
| US60/123,945 | 1999-03-12 | ||
| US60/123,949 | 1999-03-12 | ||
| US13643799P | 1999-05-28 | 1999-05-28 | |
| US13643699P | 1999-05-28 | 1999-05-28 | |
| US13643999P | 1999-05-28 | 1999-05-28 | |
| US13713199P | 1999-05-28 | 1999-05-28 | |
| US13756799P | 1999-05-28 | 1999-05-28 | |
| US13712799P | 1999-05-28 | 1999-05-28 | |
| US60/137,567 | 1999-05-28 | ||
| US60/137,131 | 1999-05-28 | ||
| US60/137,127 | 1999-05-28 | ||
| US60/136,439 | 1999-05-28 | ||
| US60/136,437 | 1999-05-28 | ||
| US60/136,436 | 1999-05-28 | ||
| US60/141,448 | 1999-06-29 | ||
| US14144899A | 1999-06-30 | 1999-06-30 | |
| US15111499P | 1999-08-27 | 1999-08-27 | |
| US60/151,114 | 1999-08-27 | ||
| US15252499P | 1999-09-03 | 1999-09-03 | |
| US60/152,524 | 1999-09-03 | ||
| US15665399A | 1999-09-09 | 1999-09-09 | |
| US15655599P | 1999-09-29 | 1999-09-29 | |
| US15663399P | 1999-09-29 | 1999-09-29 | |
| US15663499P | 1999-09-29 | 1999-09-29 | |
| US60/156,555 | 1999-09-29 | ||
| US60/156,653 | 1999-09-29 | ||
| US60/156,633 | 1999-09-29 | ||
| US60/156,634 | 1999-09-29 | ||
| US15728099P | 1999-10-01 | 1999-10-01 | |
| US15728199P | 1999-10-01 | 1999-10-01 | |
| US15729399P | 1999-10-01 | 1999-10-01 | |
| US15728299P | 1999-10-01 | 1999-10-01 | |
| US15729499P | 1999-10-01 | 1999-10-01 | |
| US60/157,294 | 1999-10-01 | ||
| US60/157,293 | 1999-10-01 | ||
| US60/157,280 | 1999-10-01 | ||
| US60/157,281 | 1999-10-01 | ||
| US60/157,282 | 1999-10-01 | ||
| US41676099A | 1999-10-12 | 1999-10-12 | |
| US41704499A | 1999-10-12 | 1999-10-12 | |
| US09/417,044 | 1999-10-12 | ||
| US09/416,760 | 1999-10-12 | ||
| PCT/US1999/024065 WO2000022131A2 (en) | 1998-10-13 | 1999-10-13 | Non-endogenous, constitutively activated human g protein-coupled receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010000087A Division JP2010142235A (ja) | 1998-10-13 | 2010-01-04 | 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003525018A JP2003525018A (ja) | 2003-08-26 |
| JP2003525018A6 JP2003525018A6 (ja) | 2004-07-08 |
| JP2003525018A5 true JP2003525018A5 (enExample) | 2006-11-09 |
Family
ID=27792453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000576021A Withdrawn JP2003525018A (ja) | 1998-10-13 | 1999-10-13 | 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2003525018A (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1249087C (zh) * | 1999-09-24 | 2006-04-05 | 索尔瓦药物有限公司 | 新的人g蛋白偶联受体 |
-
1999
- 1999-10-13 JP JP2000576021A patent/JP2003525018A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baud et al. | EMR1, an unusual member in the family of hormone receptors with seven transmembrane segments | |
| US20060233792A1 (en) | Train-R: a cysteine rich member of the TNF-receptor family | |
| CA2122491A1 (en) | Tgf-.beta. type receptor cdnas and uses therefor | |
| JP2005520834A5 (enExample) | ||
| CA2231748A1 (en) | Novel g-protein coupled receptor (hfgan72x) | |
| EP1019502A2 (en) | Human orphan receptor ntr-1 | |
| JP2000083669A (ja) | Ｃｘｃｒ４ケモカイン受容体のヒトスプライス変異体ｃｘｃｒ４ｂ | |
| JPH10201492A (ja) | 新規７−トランスメンブラン受容体をコードしているｃＤＮＡクローンＨＥ８ＣＳ４１ | |
| JP2001525178A (ja) | ヒト１１ｃｂスプライス変異体に対するアゴニストおよびアンタゴニストの探索方法 | |
| Remy et al. | The porcine follitropin receptor: cDNA cloning, functional expression and chromosomal localization of the gene | |
| Beutler et al. | Retrovirus‐mediated expression of an artificial β‐endorphin precursor in primary fibroblasts | |
| JP2000510690A (ja) | 哺乳類混合リンパ球受容体、ケモカイン受容体（ｍｍｌｒ―ｃｃｒ） | |
| US6447996B1 (en) | Galanin receptors, nucleic acids, transformed cells and uses thereof | |
| JP2002505872A (ja) | ７回膜貫通ｇタンパク質共役受容体ｅｃｒ６７３ | |
| JP2003525018A5 (enExample) | ||
| AU748167B2 (en) | Novel nucleic acid and polypeptide | |
| JP2002517222A (ja) | Ｇｐｒ３５ａ受容体 | |
| US6998244B1 (en) | Cloning and expression of a novel 5-HT4 receptor | |
| WO2000049170A1 (en) | MURINE 11cby RECEPTOR | |
| JP2002512016A (ja) | Ｅｄｇファミリー遺伝子、ヒトｈ２１８ | |
| TW442494B (en) | Novel, ATP-sensitive potassium-channel proteins and genes for the same | |
| JPH1118782A (ja) | 新規なヒト・ニューロテンシン・レセプター２型およびそのスプライス変種 | |
| AU753400C (en) | Orphan receptors | |
| WO2001046414A1 (fr) | Nouvelle proteine receptrice couplee a la proteine de fixation de guanosine triphosphate, bg26 | |
| KR970707155A (ko) | 사람 스탄니오칼신-알파(Human stanniocalcin-alpha) |